Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sage Therapeutics, Inc. < Previous 1 2 Next > Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates October 29, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio October 17, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 October 15, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease October 08, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program September 26, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress July 31, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor July 24, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 July 17, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress April 25, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease April 17, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 April 11, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Upcoming March Investor Conferences February 28, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress February 14, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 January 31, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Changes to Board of Directors January 08, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 January 02, 2024 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. December 14, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Present at Upcoming November Investor Conferences November 08, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress November 07, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023 October 24, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease October 18, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Upcoming September Investor Conferences September 06, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement August 31, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress August 07, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023 August 04, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder August 04, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference June 05, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Upcoming May Investor Conferences May 03, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
